Literature DB >> 26673353

Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer.

B W Kang1, A N Seo2, S Yoon1, H I Bae2, S W Jeon3, O K Kwon4, H Y Chung4, W Yu4, H Kang5, J G Kim6.   

Abstract

BACKGROUND: This study explored the prognostic impact of tumor-infiltrating lymphocytes (TILs) and investigated whether three histologic subtypes (lymphoepithelioma-like carcinoma, carcinoma with Crohn's disease-like lymphoid reaction, and conventional-type adenocarcinoma) could stratify a prognostic subset for patients with Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC).
MATERIALS AND METHODS: After reviewing 1318 consecutive cases of surgically resected or endoscopic submucosal dissected gastric cancers, 120 patients were identified as EBV-positive using EBV-encoded RNA in situ hybridization. The evaluation of the percentage of intratumoral (iTu-) and stromal (str-) TILs was carried out, and the cases were also subclassified into three histologic subtypes as noted above.
RESULTS: Among the 120 patients, 73 patients (60.8%) and 60 patients (50.0%) were determined as str-TIL-positive and iTu-TIL-positive, respectively. In a univariate analysis, str-TIL-positivity was significantly associated with longer recurrence-free survival (RFS; P = 0.002) and disease-free survival (DFS; P = 0.008), yet not overall survival (OS; P = 0.145). While iTu-TIL-positivity has a tendency of favorable outcome indicator for DFS and OS, but statistically significant differences were not shown, respectively (RFS, P = 0.058; DFS, P = 0.151; OS, P = 0.191). In a multivariate analysis using a Cox proportional hazard model adjusted for age, pTNM stage, lymphatic invasion, perineural invasion, and venous invasion; histologic subtype, WHO classification, and str-TIL-positivity were independently or tentatively associated with favorable RFS (hazard ratio [HR] = 12.193, 95% confidence interval [95% CI] 1.039-143.055, P = 0.047) or DFS (HR = 4.836, 95% CI 0.917-25.525, P = 0.063).
CONCLUSION: The histologic subclassification and TILs can be used to predict RFS and DFS for patients with EBVaGC.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Epstein–Barr virus-associated gastric cancer; gastric cancer; host immune reaction; prognosis; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2015        PMID: 26673353     DOI: 10.1093/annonc/mdv610

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  55 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.

Authors:  Zhi-Hua Zhou; Cheng-Dong Ji; Jiang Zhu; Hua-Liang Xiao; Hai-Bin Zhao; You-Hong Cui; Xiu-Wu Bian
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-08       Impact factor: 4.553

3.  Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.

Authors:  Joo Yeon Kim; Woo Gyeong Kim; Chae Hwa Kwon; Do Youn Park
Journal:  Gastric Cancer       Date:  2019-05-31       Impact factor: 7.370

4.  Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.

Authors:  Su-Jin Shin; Sang Yong Kim; Yoon Young Choi; Taeil Son; Jae-Ho Cheong; Woo Jin Hyung; Sung Hoon Noh; Chung-Gyu Park; Hyoung-Il Kim
Journal:  Oncologist       Date:  2019-03-20

5.  Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.

Authors:  Kohei Yamashita; Masaaki Iwatsuki; Kazuto Harada; Kojiro Eto; Yukiharu Hiyoshi; Takatsugu Ishimoto; Yohei Nagai; Shiro Iwagami; Yuji Miyamoto; Naoya Yoshida; Yoshihiro Komohara; Jaffer A Ajani; Hideo Baba
Journal:  Gastric Cancer       Date:  2019-08-26       Impact factor: 7.370

Review 6.  Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Authors:  Smita S Joshi; Steven B Maron; Daniel V Catenacci
Journal:  Future Oncol       Date:  2017-11-02       Impact factor: 3.404

7.  Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report.

Authors:  Ching Ying Lin; Pareen Mehta; Kevin M Waters; Elena Chang; Andrew Hendifar; Arsen Osipov; Miguel Burch; De-Chen Lin; Alexandra Gangi; May Cho; Jun Gong
Journal:  AME Case Rep       Date:  2021-07-25

Review 8.  Outlooks on Epstein-Barr virus associated gastric cancer.

Authors:  Madiha Naseem; Afsaneh Barzi; Christine Brezden-Masley; Alberto Puccini; Martin D Berger; Ryuma Tokunaga; Francesca Battaglin; Shivani Soni; Michelle McSkane; Wu Zhang; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2018-03-31       Impact factor: 12.111

9.  Bioinformatics analysis of the prognosis and biological significance of VCAN in gastric cancer.

Authors:  Xiao-Yan Huang; Jin-Jian Liu; Xiong Liu; Yao-Hui Wang; Wei Xiang
Journal:  Immun Inflamm Dis       Date:  2021-02-25

10.  The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.

Authors:  Xiao-Li Wei; Qian-Wen Liu; Fu-Rong Liu; Sha-Sha Yuan; Xiao-Fen Li; Jia-Ning Li; An-Li Yang; Yi-Hong Ling
Journal:  Oncoimmunology       Date:  2021-06-17       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.